Business Context and Reporting Period
Company: Proteon Therapeutics, Inc. (Note: Input metadata lists "Protara," but the filing text identifies "Proteon Therapeutics, Inc.")
Filing Type: Form 8-K (Current Report)
Date of Report: May 8, 2019
Reporting Period: First Quarter ended March 31, 2019
Status: Emerging Growth Company
Key Financial Metrics
This Form 8-K serves as a notification of the issuance of a press release regarding financial results. The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained in the attached press release (Exhibit 99.1), which is incorporated by reference but not included in the provided text.
Material Changes
The filing does not contain specific data to compare current period performance against prior periods. It solely references the announcement of Q1 2019 results.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on May 8, 2019, announcing its financial results for the first quarter ended March 31, 2019.
Legal Disclaimer: The information under Item 2.02 and the attached exhibit is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that Section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Press Release (Exhibit 99.1) as they are not listed in the 8-K body.
- Confirm the company name is Proteon Therapeutics, Inc., distinct from the "Protara" metadata provided.
- Review the full text of the May 8, 2019 press release for any forward-looking statements or operational updates not summarized in this 8-K.
- Check for any subsequent filings that may update the Q1 2019 results or provide additional context on the company's liquidity.